Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Nuevo León, México.
Hospital de Especialidades Carlos Andrade Marín, Quito, Ecuador.
Vasc Endovascular Surg. 2023 Jul;57(5):451-455. doi: 10.1177/15385744231154089. Epub 2023 Jan 22.
The gold standard for patients with carotid body tumors (CBT) is surgical resection; nevertheless, some patients are unfit for surgery or, for other reasons, could not be operated on. Active surveillance has been known to be a reasonable strategy for these cases. This study aimed to evaluate tumor growth in unoperated patients with CBTs.
A retrospective review of all unoperated patients with CBT from a single academic hospital diagnosed between 2014 and 2021 was performed. Results of nonparametric testing were presented using the median and ranges for Mann-Whitney-U or Kruskal-Wallis. Significance was defined as a 2-tailed P < .05.
The cohort included a total of 31 patients, with a median age of 60 years (range: 37-80 years), of which 27 (87.1%) were females. The patients live at a median altitude of 2800 meters (range: 2756-2980 meters) above sea level. Twenty (64.5%) patients had Shamblin I tumors, eight (25.8%) patients had Shamblin II tumors, and three (9.7%) patients had Shamblin III tumors. Median CBT volume at diagnosis was 14.1 cm3 (range: .9 - 213.3 cm). Median volume at diagnosis of symptomatic tumors was substantially larger than asymptomatic tumors, 49.2 cm vs 7.9 cm, respectively (P = .03). Median growth of the tumors during a median 15-month follow-up (range: 3-43 months) was 3.3 cm (range: 0-199.9 cm). Overall, 77% (n = 24) of the CBTs grew at least 1 cm.
Most patients in the present study had tumor growth by at least 1 cm, with a median tumor growth of 3.3 cm. In the present study tumor growth was shown to be greater than other low altitude CBT active surveillance studies; therefore, surgical resection should be recommended in patients with CBT living at high altitudes.
对于颈动脉体瘤（CBT）患者，金标准是手术切除；然而，有些患者不适合手术，或者由于其他原因无法进行手术。对于这些病例，主动监测已被证明是一种合理的策略。本研究旨在评估未手术的 CBT 患者的肿瘤生长情况。
对 2014 年至 2021 年间在一家学术医院诊断的所有未手术的 CBT 患者进行了回顾性分析。非参数检验的结果用中位数和范围表示，采用 Mann-Whitney-U 或 Kruskal-Wallis 检验。双侧 P <.05 定义为有统计学意义。
该队列共纳入 31 例患者，中位年龄 60 岁（范围：37-80 岁），其中 27 例（87.1%）为女性。患者生活在海拔中位数 2800 米（范围：2756-2980 米）以上的地方。20 例（64.5%）患者为 Shamblin I 型肿瘤，8 例（25.8%）患者为 Shamblin II 型肿瘤，3 例（9.7%）患者为 Shamblin III 型肿瘤。诊断时 CBT 体积的中位数为 14.1cm3（范围：.9 - 213.3cm）。症状性肿瘤的诊断体积明显大于无症状性肿瘤，分别为 49.2cm 和 7.9cm（P =.03）。在中位 15 个月（范围：3-43 个月）的随访期间，肿瘤的中位生长为 3.3cm（范围：0-199.9cm）。总的来说，77%（n = 24）的 CBT 至少增长了 1cm。
本研究中大多数患者的肿瘤至少增长了 1cm，肿瘤的中位生长为 3.3cm。本研究显示肿瘤生长大于其他低海拔 CBT 主动监测研究；因此，应建议生活在高海拔地区的 CBT 患者进行手术切除。
